Table 2.

Subgroup analysis of efficacy and safety outcome of galcanezumab for the treatment of migraine

	Efficacy				Safety
	50% ≥ response		MHD		TEAE
	RR (95% CI)	P value	WMD (95% CI)	P value	RR (95% CI)	P value
1. 120 mg Galcanezumab
3 months	1.469 (1.166, 1.850)	0.006	−2.090 (−3.237, − 0.943)	0.000	1.144 (1.003, 1.304)	0.045
6 months	1.513 (1.286, 1.779)	0.013	−1.774 (−2.256, − 1.291)	0.000	1.033 (0.950, 1.123)	0.443
2. 240 mg Galcanezumab
3 months	1.589 (1.270, 1.987)	0.013	−1.880 (−2.983, −0.777)	0.001	1.155 (1.014, 1.316)	0.030
6 months	1.582 (1.406, 1.780)	0.000	−1.839 (−2.324, − 1.354)	0.000	1.170 (1.082, 1.266)	0.000
3. 300 mg Galcanezumab
1 month	N/A	N/A	N/A	N/A	1.286 (0.788, 2.097)	0.314
3 months	1.509 (1.166, 1.954)	0.000	−1.200 (−2.012, −0.388)	0.004	1.087 (0.927, 1.275)	0.302
6 months	1.147 (0.928, 1.418)	0.000	−0.620 (−1.565, 0.325)	0.198	0.935 (0.693, 1.261)	0.659

RR Relative Risk, CI Confidence Interval, N/A Not Applicable